MACPAC ‘Undeterred’ By Lukewarm Reception Of Accelerated Drug Approval Recommendation

Executive director Schwartz suggests Congress may turn its attention to the advisory commission’s proposal to revise Medicaid coverage for drugs approved under the accelerated approval pathway in the next year or two.